India Bioceramics Market Overview, 2031

Key Insights

• The Indian bioceramics market operates within a healthcare environment characterized by one of the world's largest patient pools for musculoskeletal diseases. India is grappling with a significant rise in joint health issues, driven by the dual impact of an aging population and rapidly changing lifestyle habits. According to the Indian Council of Medical Research (ICMR), the number of people affected by osteoarthritis (OA) in India skyrocketed from approximately 23.46 million in 1990 to 62.35 million in 2019. The ICMR also published results stating that almost 22-39 percent of Indian adults have osteoarthritis symptoms. A 2025 meta-analysis published in the Indian Journal of Orthopaedics, covering over 50 studies with more than 25,000 participants, confirmed that osteoarthritis afflicts 22–39% of Indians over 40. Osteoarthritis is now recognized as a leading cause of disability, accounting for 1.48% of all years lived with disability in 2019. Over 54.44 million Indians live with osteoarthritis, a condition closely linked with obesity, diabetes, and hypertension, while 4.22 million suffer from rheumatoid arthritis. Approximately 5 lakh (500,000) primary knee and hip replacements are performed annually in India. However, the actual number of patients needing surgery is significantly higher, representing a substantial treatment gap. The nation is now entering a critical phase where tens of thousands of earlier implants are beginning to loosen, wear out, or fail, as most implants last 20–25 years.
• India's healthcare delivery model for Bioceramics devices is defined by the complete absence of a fully operational, centralized National Joint Registry (NJR) despite the expanding volume of total hip and knee arthroplasties. The Indian Joint Registry (IJR), established by the Indian Society of Hip and Knee Surgeons (ISHKS) in 2005, has collected data on 34,478 total knee arthroplasties and 3,604 total hip arthroplasties. However, the registry experienced a significant drop in participation, reflecting challenges in maintaining consistent engagement. The Indian Orthopaedic Association (IOA) has urged the government to establish a "National Joint Replacement Registry" to regulate medical implants and drugs for patients' safety. In many countries, NJRs are a vital part of orthopedic practice, helping surgeons monitor implant outcomes, improve techniques, and guide health policy.
• Regulatory oversight for medical devices in India is administered by the Central Drugs Standard Control Organization (CDSCO) under the Medical Devices Rules, 2017, which enforce a risk-based classification system. Orthopedic implants are classified as Class C (moderate to high risk) devices. To manufacture, import, sell, or distribute orthopedic implants in India, a medical device license (MD 5, MD 9, MD 15, or MD 42) is required. In April 2025, CDSCO issued Addendum No. 0152, emphasizing that all medical devices coming into direct or indirect contact with the human body must comply with biocompatibility testing requirements in line with the IS/ISO 10993 series of standards. The Medical Devices Rules, 2017, have laid down the standards for manufacturing and importing medical devices in India, ensuring compliance with internationally accepted safety and quality control standards. The Indian bioceramics market is characterized by a dynamic interplay between domestic manufacturers, such as Ceramat, Hindgrow Hussain, and SCTIMST, and international suppliers.

Market Outlook

• According to the research report, "India Bioceramics Market Outlook, 2031," published by Bonafide Research, the India Bioceramics Market is anticipated to grow at more than 9.89% CAGR from 2026 to 2031.
• A defining characteristic of India's bioceramics market is the convergence of one of the world's largest patient burdens with an evolving but still fragmented implant surveillance infrastructure. The ICMR estimates that 22-39% of the Indian population above 50 is affected by osteoarthritis, representing a potential patient pool of over 62 million people. This massive clinical burden, combined with India's position as the country with the second-largest population aged 60 and older globally at 162.2 million in 2025, creates unprecedented demand for joint replacement procedures and Bioceramics components. However, India currently performs only approximately 350,000 to 500,000 joint replacement surgeries each year, while the actual number of patients needing surgery is significantly higher. This treatment gap represents both a substantial growth opportunity and a critical public health challenge. The Indian Joint Registry, managed by the ISHKS, has been collecting data for over six years and provides the only systematic view of arthroplasty trends in the country.
• The market also reflects India's distinctive healthcare financing landscape, where the Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (PM-JAY) scheme provides health insurance coverage for senior citizens. Under the AB-PMJAY, eligible families receive cashless health coverage up to Rs. 5 lakh per year for secondary and tertiary care. As per data available on the NHA IT System, 159,000 hospital admissions of senior citizens aged 60 years and above, amounting to Rs. 1,428.93 crore, have been authorized for total knee replacement under the scheme as of November 2025. Government hospitals are also expanding joint replacement capacity. In the dental sector, India's dental implant market is experiencing significant growth, driven by rising disposable incomes, increasing awareness of oral health, and the expanding middle class.
• India's bioceramics market also benefits from a distinctive and growing domestic manufacturing ecosystem. Ceramat, an innovation-led Indian company, specializes in Bioceramics and advanced ceramic solutions for healthcare applications, supplying high-purity Hydroxyapatite (HAp), β-TCP, CDHA, and blasting media in powder and granule forms for use in implants, bone grafts, and regenerative research. Hindgrow Hussain Private Limited is a deep-tech biomedical startup dedicated to advancing cost-effective and biocompatible medical devices, with core innovation in zirconia-based bone graft substitutes and dental implants. The Sree Chitra Tirunal Institute for Medical Sciences and Technology (SCTIMST) has launched two innovative drug-eluting bone graft products, CASPRO and BONYX. BONYX contains Bioceramics beads for local drug delivery in bone, with ceramic beads featuring multi-modal porosity that makes up the bone mineral composition through a patented process. CASPRO is a bioactive, mouldable and self-setting bone cement designed for drug delivery in bone. Lucid Implants specializes in custom-made medical devices, providing custom ceramic, polymer, and metal hard tissue implants as bone replacements.

Market Dynamics

Driver: Massive and rapidly growing patient population driven by demographic aging, lifestyle factors, and the obesity epidemic
India's bioceramics market is fundamentally driven by one of the world's largest patient pools for osteoarthritis and musculoskeletal diseases. ICMR data shows that the number of people affected by osteoarthritis in India skyrocketed from approximately 23.46 million in 1990 to 62.35 million in 2019. The Indian Council of Medical Research estimates that 22-39% of the Indian population above 50 years is affected by osteoarthritis. Osteoarthritis is recognized as a leading cause of disability, accounting for 1.48% of all years lived with disability in 2019. A 2025 meta-analysis published in the Indian Journal of Orthopaedics, covering over 50 studies with more than 25,000 participants, confirmed that osteoarthritis afflicts 22-39% of Indians over 40. The condition is closely linked with obesity, diabetes, and hypertension, all of which are rising rapidly in India. Excess weight puts extra pressure on the joints, especially the knees and hips, leading to early onset osteoarthritis. With India's population aged 60 and older projected to reach 194 million by 2031, the burden of osteoarthritis is expected to continue its upward trajectory. Musculoskeletal disorders are increasingly affecting not just the elderly but also young adults burdened by sedentary lifestyles and long hours of desk work. The World Health Organization COPCORD survey has revealed that over 195 million Indians nearly one in six people suffer from arthritis-related pain.



Challenge: Absence of a fully operational National Joint Registry and fragmented implant surveillance infrastructure
One of the most significant challenges facing India's bioceramics market is the lack of a centralized, fully operational National Joint Registry (NJR). In many countries, NJRs are a vital part of orthopedic practice, helping surgeons monitor implant outcomes, improve techniques, and guide health policy. The absence of such a registry in India, despite the expanding volume of total hip and knee arthroplasties, limits the ability to systematically monitor implant performance, track revision rates, and provide early warnings of device failures. The Indian Joint Registry (IJR), established by the Indian Society of Hip and Knee Surgeons in 2005, has collected data on 34,478 TKAs and 3,604 THAs, but experienced a significant drop in participation. Experts have urged the government to establish a "National Joint Replacement Registry" to regulate medical implants and drugs for patients' safety. The fragmented nature of implant surveillance also complicates post-market monitoring of Bioceramics devices and limits the ability to conduct large-scale clinical evaluations of implant performance. Additionally, revision surgeries are far more complex than primary replacements and demand specialized training, planning, and experience. India is now entering an era where trained "revision" knee and hip replacement surgeons are no longer optional; they are essential.

Trend: Development of domestic Bioceramics manufacturing capabilities and import substitution
India is experiencing a significant strategic push toward domestic manufacturing of Bioceramics materials and medical devices, driven by the imperative to reduce import dependence and make advanced healthcare more affordable and accessible. Ceramat, an innovation-led Indian company, specializes in high-purity Hydroxyapatite (HAp), β-TCP, CDHA, and blasting media for use in implants, bone grafts, and regenerative research. The company's expertise in high-purity, biocompatible materials positions it to serve fast-growing applications across orthopedics, oral care, and pharmaceuticals. Hindgrow Hussain Private Limited is a deep-tech biomedical startup dedicated to advancing cost-effective and biocompatible medical devices, with core innovation in zirconia-based bone graft substitutes and dental implants. The Sree Chitra Tirunal Institute for Medical Sciences and Technology (SCTIMST), a premier government research institution, has launched two innovative drug-eluting bone graft products, CASPRO and BONYX. BONYX contains Bioceramics beads with multi-modal porosity for local drug delivery in bone, designed to handle bone infections. CASPRO is a bioactive, mouldable and self-setting bone cement designed for drug delivery in bone. Lucid Implants specializes in custom-made medical devices, providing custom ceramic, polymer, and metal hard tissue implants as bone replacements. The development of domestic manufacturing capabilities for zirconia-based bone graft substitutes, dental implants, and Bioceramics bone grafts represents a critical strategic objective for reducing import dependence and strengthening India's position in the global bioceramics market.

Policies

• CDSCO Medical Device Registration and Medical Devices Rules, 2017: All implantable Bioceramics medical devices must obtain registration with the Central Drugs Standard Control Organization (CDSCO) under the Medical Devices Rules, 2017, before they can be manufactured, imported, marketed, or distributed in India. The rules enforce a risk-based classification system (Class A-D), mandatory licensing, ISO 13485-compliant quality systems, and adherence to ISO 10993 biocompatibility standards. Orthopedic implants are classified as Class C devices (moderate to high risk). To manufacture, import, sell, or distribute orthopedic implants in India, a medical device license (MD 5, MD 9, MD 15, or MD 42) is required.
• CDSCO Biocompatibility Requirements (Addendum No. 0152): In April 2025, CDSCO issued Addendum No. 0152, emphasizing that all medical devices coming into direct or indirect contact with the human body must comply with biocompatibility testing requirements in line with the IS/ISO 10993 series of standards. This addendum provides additional clarity on biocompatibility, sterility, and labelling requirements for medical devices.
• Ayushman Bharat PM-JAY and Government Hospital Expansion: The Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (PM-JAY) scheme provides health insurance coverage for senior citizens. Under the AB-PMJAY, eligible families receive cashless health coverage up to Rs. 5 lakh per year for secondary and tertiary care, including procedures such as knee replacement. The scheme has been expanded to cover 60 million senior citizens of age 70 years and above. As per data available on the NHA IT System, 159,000 hospital admissions of senior citizens aged 60 years and above, amounting to Rs. 1,428.93 crore, have been authorized for total knee replacement under the scheme as of November 2025. Knee Joint Replacement facility is already available in most government hospitals.
• Indian Joint Registry (IJR) and Implant Surveillance: The Indian Joint Registry, established by the Indian Society of Hip and Knee Surgeons (ISHKS) in 2005, serves as the primary implant surveillance infrastructure. The registry has collected data on 34,478 total knee arthroplasties and 3,604 total hip arthroplasties. The Indian Orthopaedic Association (IOA) has urged the government to establish a "National Joint Replacement Registry" to regulate medical implants and drugs for patients' safety.
• Clinical Practice Guidelines and Specialty Society Standards: Utilization of Bioceramics devices in India is aligned with evidence-based recommendations promoted by national professional organizations including the Indian Orthopaedic Association (IOA), the Indian Society of Hip and Knee Surgeons (ISHKS), and the Indian Dental Association (IDA). These organizations provide clinical guidelines and continuing education for orthopedic and dental professionals, informed by Indian Joint Registry data and international best practices.

Segment Analysis

India Bioceramics Market By Type
• Bioinert Ceramics represents the largest product category in India, driven by the massive and rapidly growing volume of joint replacement procedures. Approximately 5 lakh primary knee and hip replacements are performed annually in India. Bioinert ceramics maintain their physical integrity in the body and are ideal for load-bearing applications. Alumina and zirconia femoral heads are critical components in hip replacements, with ceramic implants offering superior wear resistance and longevity compared to metal alternatives. The growing number of arthroplasties and the rising demand among younger patients drives demand for durable bioinert ceramic components. In dental applications, bioinert zirconia is increasingly preferred for implants and restorations, supported by the rapid growth of India's dental implant market.
• Bioactive Ceramics maintains an important position in India, particularly in applications requiring bone bonding, including hydroxyapatite coatings, bioactive glass, and bone graft substitutes. Ceramat supplies high-purity Hydroxyapatite (HAp), β-TCP, and CDHA for use in implants, bone grafts, and regenerative research. The SCTIMST has launched BONYX, a drug-eluting bone graft product containing Bioceramics beads with multi-modal porosity for local drug delivery in bone. Bioactive ceramics are used to promote osseointegration in both orthopedic and dental surgeries, with the high prevalence of osteoarthritis and the growing volume of joint replacement procedures driving demand.
• Bioresorbable Ceramics represents a growing segment in India, driven by increasing demand for temporary implants, bone void fillers, and drug delivery systems. These materials gradually dissolve and are replaced by natural bone, making them valuable in applications where permanent implants are unnecessary. The development of domestic manufacturing capabilities for bioresorbable materials, such as Hindgrow Hussain's zirconia-based bone graft substitutes, positions India to capture growth in this segment. The increasing number of trauma cases and the growing demand for bone regeneration solutions drive demand for bioresorbable ceramic materials.

India Bioceramics Market By Material
• Zirconia represents a leading material category in India, driven by the country's rapidly growing dental implant market and emerging orthopedic applications. Zirconia's superior fracture toughness and aesthetic translucency make it the preferred material for dental implants and restorations. Hindgrow Hussain Private Limited specializes in zirconia-based bone graft substitutes and dental implants. The growing emphasis on aesthetics in dental care and the expanding middle class are driving zirconia adoption. The Indian dental implant market is one of the fastest growing implant markets worldwide.
• Alumina maintains an important position in Indian orthopedics, with alumina ceramic heads widely used in hip replacements. Approximately 5 lakh primary knee and hip replacements are performed annually in India. Alumina's high hardness and wear resistance make it suitable for load-bearing orthopedic applications. The complete dependence on imported alumina components for many applications represents a strategic vulnerability that domestic manufacturers are working to address.
• Calcium Phosphate is a critical material category encompassing hydroxyapatite and β-tricalcium phosphate for bone graft substitutes and implant coatings. Ceramat supplies high-purity Hydroxyapatite (HAp), β-TCP, and CDHA in powder and granule forms for use in implants, bone grafts, and regenerative research. The SCTIMST's BONYX product contains ceramic beads with multi-modal porosity that make up the bone mineral composition. The high prevalence of osteoarthritis with over 54.44 million Indians living with the condition and the growing volume of joint replacement procedures drive demand for calcium phosphate-based bone graft materials.
• Calcium Sulfate holds a niche position in the Indian market, primarily used as a synthetic bone void filler and antibiotic-eluting carrier for the treatment of osteomyelitis and infected surgical sites. SCTIMST's CASPRO is a bioactive, mouldable and self-setting bone cement composed of synthetic medical-grade basanite (calcium sulfate hemihydrate mineral), fortified with phosphate ions.
• Others (Carbon-based Ceramic, Bioactive Glass) includes carbon-based ceramics for cardiovascular applications, bioactive glass for bone regeneration, and emerging Bioceramics materials. Ceramat supplies advanced Bioceramics materials for implants, bone regeneration, and healthcare innovations. Indian research institutions continue to explore novel Bioceramics materials.

India Bioceramics Market By Application
• Orthopedics represents the largest application segment in India, driven by the substantial burden of osteoarthritis and the growing volume of joint replacement procedures. Approximately 5 lakh primary knee and hip replacements are performed annually in India. ICMR estimates that 22-39% of the Indian population above 50 years is affected by osteoarthritis, representing a potential patient pool of over 62 million people. Orthopedic applications include ceramic femoral heads, ceramic knee components, calcium phosphate bone grafts, and hydroxyapatite coatings. The rising number of revision surgeries, as India enters a critical phase where tens of thousands of earlier implants are beginning to fail, is driving demand for advanced ceramic components. Revision surgeries are far more complex than primary replacements and demand specialized training, planning, and experience.
• Dental represents the second-largest application segment, driven by the growing demand for aesthetic dental restorations and implants. Zirconia has emerged as the preferred material for implants, crowns, and bridges. Hindgrow Hussain Private Limited specializes in zirconia-based dental implants. The growing emphasis on aesthetics in dental care, rising disposable incomes, and the expanding middle class are driving demand for zirconia-based dental bioceramics. India is one of the fastest growing implant markets worldwide.
• Biomedical & Others encompasses tissue engineering scaffolds, drug delivery systems, cardiovascular applications, surgical instruments, and wound healing products. The SCTIMST's BONYX product, containing Bioceramics beads with multi-modal porosity for local drug delivery in bone, represents an innovative application of bioceramics in drug delivery. CASPRO is a bioactive, mouldable and self-setting bone cement designed for drug delivery in bone. Lucid Implants specializes in custom ceramic, polymer, and metal hard tissue implants as bone replacements. Indian research institutions continue to investigate novel Bioceramics materials for emerging biomedical applications.

Major Bioceramics Manufacturers Operating in India
• Ceramat is an innovation-led Indian company specializing in Bioceramics and advanced ceramic solutions for healthcare and industrial applications. The company supplies high-purity Hydroxyapatite (HAp), β-TCP, CDHA, and blasting media in powder and granule forms for use in implants, bone grafts, and regenerative research. Ceramat is ISO 13485 compliant and has established an active commercial arm on orthopaedic & dental bioceramics catering to medical hard tissue implantables. Ceramat synthesizes nanocrystalline grade hydroxyapatite which can be utilized in bone repair and bone regeneration applications.
• Hindgrow Hussain Private Limited is a deep-tech biomedical startup dedicated to advancing cost-effective and biocompatible medical devices, with core innovation in zirconia-based bone graft substitutes and dental implants. The company designs, develops, and manufactures zirconia-based bone graft substitutes, dental implants, and supportive biomaterials tailored for high performance, safety, and long-term patient compatibility.
• Sree Chitra Tirunal Institute for Medical Sciences and Technology (SCTIMST), a premier government research institution, has launched two innovative drug-eluting bone graft products, CASPRO and BONYX. BONYX contains Bioceramics beads with multi-modal porosity for local drug delivery in bone, designed to handle bone infections. CASPRO is a bioactive, mouldable and self-setting bone cement designed for drug delivery in bone. Both products have undergone validation for regulatory approval as per international standards.
• Lucid Implants specializes in custom-made medical devices, providing custom ceramic, polymer, and metal hard tissue implants as bone replacements. The company helps surgeons predict and validate a medical device for a specific patient.
• International players with significant presence include Zimmer Biomet, Stryker, DePuy Synthes, Smith & Nephew, CeramTec, Straumann, and Dentsply Sirona. The market is also supported by distributors and procurement organizations that provide commercialization, maintenance, and supply chain support.

India Bioceramics Procedure Economics

• Bioceramics implantation in India operates within a mixed healthcare financing landscape comprising government-funded schemes, private health insurance, and out-of-pocket payments. The Ayushman Bharat PM-JAY scheme provides health insurance coverage for senior citizens, with 159,000 hospital admissions of senior citizens aged 60 years and above authorized for total knee replacement under the scheme as of November 2025.
• In private hospitals and specialized orthopedic centers, the total cost of joint replacement surgery including the ceramic component, hospital charges, surgeon fees, and post-operative management varies significantly depending on hospital category, implant type, and geographic location. Knee replacement surgery costs Rs 1.5-3 lakh which is unaffordable to many. The choice of bearing surface material ceramic-on-ceramic, ceramic-on-polyethylene, or metal-on-polyethylene significantly influences the cost and longevity of the implant.
• Government hospitals are expanding joint replacement capacity, with the number of surgeries performed in government hospitals rising. Knee Joint Replacement facility is already available in most government hospitals.
• In the dental sector, the cost of dental implants varies significantly depending on the material, manufacturer, and clinic location. The increasing availability of domestically manufactured zirconia implants and Bioceramics bone graft materials is expected to make dental implant procedures more affordable and accessible to a broader patient population.
• Long-term costs include device monitoring, imaging surveillance, and revision procedures. As India enters a critical phase where tens of thousands of earlier implants are beginning to fail, the demand for revision surgeries and the associated costs are expected to rise significantly. Revision surgeries are typically more complex, costly, and carry higher risks compared to primary procedures.

India Bioceramics Market By End User
• Hospitals and Surgical Centers dominate Bioceramics utilization in India. Approximately 5 lakh primary knee and hip replacements are performed annually in India. Government hospitals and private hospital chains perform the majority of orthopedic procedures. Private hospitals continue to perform a significant proportion of joint replacement procedures, with patients seeking premium ceramic implant technologies.
• Dental Clinics and Laboratories represent a significant end-user category, driven by the growing demand for aesthetic dental restorations and implants. Dental clinics provide patient-facing implant and restorative services, while dental laboratories manufacture crowns, bridges, and custom abutments using CAD/CAM technology. The adoption of digital dentistry technologies, including CAD/CAM systems, is driving demand for pre-sintered zirconia blocks and other advanced ceramic forms.
• Others includes medical device manufacturers (OEMs), academic research institutions, and biotechnology companies. Indian manufacturers such as Ceramat, Hindgrow Hussain, and Lucid Implants represent domestic manufacturing capability in bioceramics and regenerative medicine. The SCTIMST, a premier government research institution, continues to develop innovative Bioceramics products for bone regeneration and drug delivery. Indian research institutions continue to advance Bioceramics research and development, supported by agencies such as the Indian Council of Medical Research (ICMR) and the Department of Biotechnology (DBT).

India Bioceramics Market By Form
• Liquid (Injectable) & Others represents a growing form segment in India, driven by the increasing adoption of ready-to-use formulations including injectable bone cements, premixed calcium phosphate pastes, flowable bone graft putties, and pre-sintered dental blocks for CAD/CAM milling. The adoption of digital dentistry technologies supports demand for pre-sintered zirconia blocks and other ready-to-use forms. SCTIMST's CASPRO is a bioactive, mouldable and self-setting bone cement designed for drug delivery in bone, which on wetting with aqueous solution forms a putty or paste that could be used for the repair of bone defects.
• Powder maintains an important position as raw material feedstock for OEM manufacturing, plasma-spray coating of metallic implants, and on-site mixing for bone graft applications. Ceramat supplies high-purity Hydroxyapatite (HAp), β-TCP, and CDHA in powder and granule forms for use in implants, bone grafts, and regenerative research. Hindgrow Hussain Private Limited develops zirconia-based bone graft substitutes. India's import trends for ceramic biomaterials reflect ongoing demand for high-purity ceramic powders, with the domestic production of these materials being a strategic priority for import substitution.

Market Outlook by Healthcare Spending and Infrastructure

• India's bioceramics market growth is linked to the country's position as the country with one of the world's largest patient pools for musculoskeletal diseases and the second-largest population aged 60 and older globally. The ICMR estimates that 22-39% of the Indian population above 50 years is affected by osteoarthritis, with over 54.44 million Indians living with the condition. Approximately 5 lakh primary knee and hip replacements are performed annually in India.
• The absence of a fully operational National Joint Registry remains a significant gap in India's healthcare infrastructure. The Indian Joint Registry, established by the Indian Society of Hip and Knee Surgeons in 2005, has collected data on 34,478 TKAs and 3,604 THAs. The Indian Orthopaedic Association has urged the government to establish a "National Joint Replacement Registry" to regulate medical implants and drugs for patients' safety.
• The future growth opportunity for bioceramics in India depends on continued investment in domestic manufacturing capabilities, the establishment of a comprehensive national joint registry, the expansion of joint replacement services to underserved populations, and the successful implementation of government health insurance schemes.
• Companies such as Ceramat, Hindgrow Hussain, and Lucid Implants represent the emerging domestic manufacturing ecosystem for bioceramics in India. The SCTIMST's BONYX and CASPRO products represent innovative government research institution-led developments in drug-eluting bone grafts. Professional organizations including the Indian Orthopaedic Association (IOA), the Indian Society of Hip and Knee Surgeons (ISHKS), and the Indian Dental Association (IDA) continue to advance the field through clinical research, guideline development, and professional education. The Indian Council of Medical Research (ICMR) and the Department of Biotechnology (DBT) continue to support research and development in medical devices and biomaterials, including bioceramics.


Considered in this report
• Historic Year: 2020
• Base year: 2025
• Estimated year: 2026
• Forecast year: 2031

Aspects covered in this report
• Bioceramics Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Type
• Bioinert Ceramics
• Bioactive Ceramics
• Bioresorbable Ceramics

By Material
• Alumina
• Zirconia
• Calcium Phosphate
• Calcium Sulfate
• Others (carbon-based ceramic, Bio activated Glass)

By Application
• Orthopedics
• Dental
• Biomedical & others

By End User
• Hospitals and Surgical Centers
• Dental Clinics and Laboratories
• Others

By Form
• Powder
• Liquid (Injectable) & Others